ACAD ACADIA PHARMACEUTICALS INC: institutional ownership and insider trading
375 funds reported holding $4.73B of ACADIA PHARMACEUTICALS INC in their latest 13F filings; in Q2 2026 funds net bought $88.0M, with 44 new positions and 37 funds selling out; over the last 12 months insiders bought $0 and sold $3.40M on the open market.
Famous investors holding ACAD
- Renaissance Technologies (Renaissance Technologies): $32.4M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $43.0M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $23.5M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $57.8M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $14.9M, 0.0% of the portfolio
- Ray Dalio (Bridgewater Associates): $1.27M, 0.0% of the portfolio
Largest institutional holders of ACAD
- BAKER BROS. ADVISORS LP — $1.09B
- BlackRock, Inc. (BLK) — $570M
- VANGUARD GROUP INC — $405M
- STATE STREET CORP (STT, STT-PG) — $230M
- VANGUARD PORTFOLIO MANAGEMENT LLC — $224M
- RTW INVESTMENTS, LP — $181M
- VANGUARD CAPITAL MANAGEMENT LLC — $146M
- DIMENSIONAL FUND ADVISORS LP — $93.5M
- GEODE CAPITAL MANAGEMENT, LLC — $85.0M
- Palo Alto Investors LP — $72.5M
Recent ACAD insider trades
- Aug 6, 2026: Schneyer Mark C. sold 20,141 shares ($587K)
- Jul 30, 2026: Thompson Elizabeth H.Z. sold 16,558 shares ($433K)
- Jun 26, 2026: Kihara James sold 11,421 shares ($298K)
- May 26, 2026: Kihara James sold 5,401 shares ($114K)
5%+ owners
- STATE STREET CORPORATION: 5.3% (Schedule 13G, filed Aug 7, 2026)
- Vanguard Portfolio Management: 5.2% (Schedule 13G, filed Apr 28, 2026)